Publications by authors named "Stuart Oliver"

Claim this Profile
W
Winner-loser effects on life history traits.
Lauren M Harrison, Oliver P Stuart, Michael D Jennions

J Evol Biol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Purging of Highly Deleterious Mutations Through an Extreme Bottleneck.
Oliver P Stuart, Rohan Cleave, Kate Pearce, Michael J L Magrath, Alexander S Mikheyev

Mol Biol Evol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genome of the Lord Howe Island Stick Insect Reveals a Highly Conserved Phasmid X Chromosome.
Oliver P Stuart, Rohan Cleave, Michael J L Magrath, Alexander S Mikheyev

Genome Biol Evol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects.
Kelong Han, Jennifer Cremer, Robert Elston, Stuart Oliver, Sharon Baptiste-Brown

Clin Pharmacol Drug Dev· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Morphological and Molecular Analysis of Australian Earwigs (Dermaptera) Points to Unique Species and Regional Endemism in the Anisolabididae Family.
Oliver P Stuart, Matthew Binns, Paul A Umina, Joanne Holloway, Dustin Severtson

Insects· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Fostamatinib on the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone: Results From In Vitro and Phase 1 Clinical Studies.
Paul Martin, Michael Gillen, David Millson, Stuart Oliver, Clive Brealey

Clin Pharmacol Drug Dev· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies.
Paul Martin, Michael Gillen, David Millson, Stuart Oliver, Clive Brealey

Drugs R D· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies.
Paul Martin, Michael Gillen, David Millson, Stuart Oliver, Clive Brealey

Clin Ther· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies.
Paul Martin, Stuart Oliver, Michael Gillen, Thomas Marbury, David Millson

Clin Ther· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine.
Susanne Johansson, Jessica Read, Stuart Oliver, Mark Steinberg, Yan Li

Clin Pharmacokinet· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML.
Hagop M Kantarjian, Mikkael A Sekeres, Vincent Ribrag, Philippe Rousselot, Guillermo Garcia-Manero, Stuart D Oliver

Clin Lymphoma Myeloma Leuk· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia.
Mike Dennis, Michelle Davies, Stuart Oliver, Roy D'Souza, Laura Pike

Cancer Chemother Pharmacol· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disposition and metabolism of the specific endothelin A receptor antagonist zibotentan (ZD4054) in healthy volunteers.
Jacqueline A Clarkson-Jones, Alison S J Kenyon, John Kemp, Eva M Lenz, Stuart D Oliver

Xenobiotica· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
Paul Martin, Stuart Oliver, Sarah-Jane Kennedy, Elizabeth Partridge, Michael Hutchison

Clin Ther· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.
Paul Martin, Stuart Oliver, Jane Robertson, Sarah-Jane Kennedy, Jessica Read

Drugs R D· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies.
Helen Tomkinson, John Kemp, Stuart Oliver, Helen Swaisland, Maria Taboada

BMC Clin Pharmacol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects.
Renli Teng, Stuart Oliver, Martin A Hayes, Kathleen Butler

Drug Metab Dispos· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Angelika Weil, Paul Martin, Robert Smith, Stuart Oliver, Peter Langmuir

Clin Pharmacokinet· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.
Helen K Tomkinson, John V Kemp, Thomas Wollseifen, Thomas Morris, Stuart D Oliver

Clin Ther· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study.
Mark P Saunders, Richard Wilson, Marc Peeters, Robert Smith, Alex Godwood, Stuart Oliver

Cancer Chemother Pharmacol· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer.
Michael Michael, Peter Gibbs, Robert Smith, Alex Godwood, Stuart Oliver

Invest New Drugs· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.
Lynn Purkins, Nolan Wood, Katie Greenhalgh, Malcolm D Eve, Stuart D Oliver

Br J Clin Pharmacol· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety.
Lynn Purkins, Nolan Wood, Katie Greenhalgh, Michael J Allen, Stuart D Oliver

Br J Clin Pharmacol· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism and disposition of the antihypertensive agent moxonidine in humans.
Minxia M He, Trent L Abraham, Thomas J Lindsay, Hans C Schaefer, Isabelle J Pouliquen, Stuart D Oliver

Drug Metab Dispos· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic effect of continuous vs intermittent dosing of dofetilide on QT interval.
Michael J Allen, Stuart D Oliver, Margaret W Newgreen, Donald J Nichols

Br J Clin Pharmacol· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis